André C. Muller (Idorsia Ltd. (SIX: IDIA))

Muller, André C. (Idorsia 202407 CEO formerly CFO before Actelion 201309– CFO before Pierre Fabre CFO)

	Organisation	Idorsia Ltd. (SIX: IDIA)
	Group	Idorsia (Group)
	Former/major organisation	Actelion Ltd. (SIX: ATLN)
	Group	Johnson & Johnson (JnJ) (Group)
	Product	aprocitentan (ACT-132577)
	Product 2	pharmaceutical

Record changed: 2024-12-31

Picture Swiss Biotech Association Swiss Biotech Days 2025 SBD25 Basel 650x200px

More documents for André C. Muller

[1] Idorsia Ltd.. (12/20/24). "Press Release: Idorsia Provides Update on the Exclusive Negotiations for the Global Rights to Aprocitentan". Allschwil....
[2] Idorsia Ltd.. (11/27/24). "Press Release: Idorsia Enters into Exclusive Negotiations for Global Rights to Aprocitentan". Allschwil....
[3] Idorsia Ltd.. (7/1/24). "Press Release: Idorsia’s Jeraygo (aprocitentan) Approved in Europe as First and Only ERA for the Treatment of Resistant Hypertension". Allschwil....
[4] Idorsia Ltd.. (2/28/24). "Press Release: Idorsia and Viatris Enter into a Significant Global Research and Development Collaboration". Allschwil....
[5] Idorsia Ltd.. (5/20/20). "Press Release: Idorsia Successfully Completes the Offering of New Shares thereby Securing Funding for the Company’s Growth Plan". Allschwil....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]